Inhibrx Inc. (INBX): Price and Financial Metrics
GET POWR RATINGS... FREE!
INBX POWR Grades
- INBX scores best on the Sentiment dimension, with a Sentiment rank ahead of 51.29% of US stocks.
- The strongest trend for INBX is in Growth, which has been heading down over the past 179 days.
- INBX's current lowest rank is in the Stability metric (where it is better than 4.64% of US stocks).
INBX Stock Summary
- With a price/sales ratio of 264.56, INHIBRX INC has a higher such ratio than 98.78% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 16.84 for INHIBRX INC; that's greater than it is for 97.23% of US stocks.
- As for revenue growth, note that INBX's revenue has grown -33.24% over the past 12 months; that beats the revenue growth of just 5.8% of US companies in our set.
- Stocks that are quantitatively similar to INBX, based on their financial statements, market capitalization, and price volatility, are NTLA, CRSP, PTGX, RNA, and RLAY.
- Visit INBX's SEC page to see the company's official filings. To visit the company's web site, go to www.inhibrx.com.
INBX Valuation Summary
- In comparison to the median Healthcare stock, INBX's price/sales ratio is 5664.58% higher, now standing at 276.7.
- Over the past 28 months, INBX's price/earnings ratio has gone down 0.6.
Below are key valuation metrics over time for INBX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INBX | 2022-11-25 | 276.7 | -37.7 | -10.5 | -12.0 |
| INBX | 2022-11-23 | 268.6 | -36.6 | -10.2 | -11.6 |
| INBX | 2022-11-22 | 273.7 | -37.3 | -10.4 | -11.8 |
| INBX | 2022-11-21 | 276.3 | -37.6 | -10.5 | -11.9 |
| INBX | 2022-11-18 | 264.2 | -36.0 | -10.0 | -11.4 |
| INBX | 2022-11-17 | 266.4 | -36.3 | -10.1 | -11.5 |
INBX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INBX has a Quality Grade of C, ranking ahead of 34.19% of graded US stocks.
- INBX's asset turnover comes in at 0.076 -- ranking 283rd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows INBX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.076 | 1 | -2.381 |
INBX Price Target
For more insight on analysts targets of INBX, see our INBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $40.50 | Average Broker Recommendation | 1.4 (Strong Buy) |
INBX Stock Price Chart Interactive Chart >
INBX Price/Volume Stats
| Current price | $28.82 | 52-week high | $45.99 |
| Prev. close | $29.00 | 52-week low | $7.67 |
| Day low | $28.63 | Volume | 202,800 |
| Day high | $29.69 | Avg. volume | 485,236 |
| 50-day MA | $27.77 | Dividend yield | N/A |
| 200-day MA | $20.24 | Market Cap | 1.26B |
Inhibrx Inc. (INBX) Company Bio
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.
Latest INBX News From Around the Web
Below are the latest news stories about INHIBRX INC that investors may wish to consider to help them evaluate INBX as an investment opportunity.
Inhibrx Announces Participation in Upcoming Investor ConferenceInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference: |
Inhibrx (INBX) Down on Updated Data From Bone Cancer StudyInhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma. |
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer CandidateInhibrx Inc (NASDAQ: INBX) announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for chondrosarcoma, a rare type of cancer that usually begins in the bones. Inhibrx presented this dataset as of May 2022 at the Annual Connective Tissue Oncology Society Conference, which included matured data on the original chondrosarcoma cohort and initial data from an additional cohort of chondrosarcoma patients with the isocitrate dehydrogenase (IDH) mutation. Related: |
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of ChondrosarcomaInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma. Inhibrx presented this dataset as of May 2022 at the Annual Connective Tissue Oncology Society (CTOS) Conference today, which included matured data on the original chondrosarcoma cohort and initial data from an |
Inhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagInhibrx ( NASDAQ:INBX ) Third Quarter 2022 Results Key Financial Results Net loss: US$35.3m (loss widened by 72% from... |
INBX Price Returns
| 1-mo | -10.44% |
| 3-mo | 72.06% |
| 6-mo | 149.96% |
| 1-year | -28.72% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -34.01% |
| 2021 | 32.45% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...